Adjuvant palbociclib strikes out in PALLAS trial

Erica Mayer explains why she believes the story of adjuvant palbociclib in hormone receptor-positive, HER2-negative, early-stage breast cancer is not yet over despite the failure of the PALLAS study to meet its primary endpoint (2:42).